- Home >
- Clinicals Trials >
- MorningLyte
Lymphoma
MorningLyte
This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated FLIPI 2-5 follicular lymphoma.
- Open at Saint-Cloud since : 25/06/2024
- Target : Adult
- Phase : Phase III
Trial description
Demonstrate the superiority of the mosunetuzumab/lenalidomide combination compared to;anti-CD20 monoclonal antibodies plus chemotherapy, with regard to survival without;progression (PFS) assessed by the independent data monitoring committee (IRC) in;blinding of treatment groups in treatment-na´ve lymphoma patients;follicular FLIPI 2-5.;PFS is defined as the time from randomization to the date of the first;documented progression or relapse of disease or death from all causes,;according to the Lugano 2014 criteria.
Url of the trialMain investigator
